Epizyme (EPZM) Highlighted on Sector Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailEpizyme (NASDAQ: EPZM) highlighted as a comp for MyoKardia (NASDAQ: MYOK), which was acquired today, at Citi. Sees EPZM worth $45-$55 in a deal.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts SGHC Limited (SGHC) at Equalweight
- EQT nears €9.6 billion deal to acquire Qiagen - Bloomberg
- RBC Capital Downgrades Tikehau Capital (TKO:FP) (TKKHF) to Sector Perform
Create E-mail Alert Related Categories
Analyst Comments, Rumors, Trader TalkRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
